In vitro administration of gold nanoparticles functionalized with MUC-1 protein fragment generates anticancer vaccine response via macrophage activation and polarization mechanism

Journal of Cancer

Volumn 6, Issue 6, 2015, Pages 583-592

  Mocan, Teodora ^a,b   Matea, Cristian ^a,b   Tabaran, Flaviu ^b,c   Iancu, Cornel ^a,b   Orasan, Remus ^a   Mocan, Lucian ^a,b  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b REGIONAL INSTITUTE OF GASTROENTEROLOGY AND HEPATOLOGY   (Romania)

^c UNIVERSITY OF AGRICULTURAL SCIENCES AND VETERINARY MEDICINE   (Romania)

Author keywords

Cancer vaccine; Macrophages; Monoclonal antibodies; Peptides

Indexed keywords

CANCER VACCINE; GOLD NANOPARTICLE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; MUCIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL POLARITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; MACROPHAGE ACTIVATION; MONOLAYER CULTURE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE;

EID: 84930204280     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.11567     Document Type: Article

References (24)

1. Mocan L, Ilie I, Tabaran FA, et al. Surface plasmon resonance-induced photoactivation of gold nanoparticles as mitochondria-targeted therapeutic agents for pancreatic cancer. Expert opinion on therapeutic targets. 2013;:1-11.
2. Iancu C, Ilie IR, Georgescu CE, et al. Applications of Nanomaterials in Cell Stem Therapies and the Onset of Nanomedicine. Particul Sci Technol. 2009;27(6):562-574.
3. Nanda R, Chennamaneni P, Gibson J, et al. Abstract P2-16-21: A randomized phase I trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel, Abraxane®) with or without mifepristone for advanced breast cancer. Cancer Res. 2013;73(24 Supplement):P2-16-21-P2-16-21.
4. Fuller S, Stewart S, Lebowitz M, Malhotra K, Ghanbari H. Inhibition of tumor growth in vivo by a nanoparticle-based therapeutic cancer vaccine targeting HAAH. Journal for immunotherapy of cancer. 2013;1(Suppl 1):P269.
5. Hobo W, Novobrantseva TI, Fredrix H, et al. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunology, Immunotherapy. 2013;62(2):285-297.
6. Liu S, Wei W, Yue H, et al. Nanoparticles-based multi-adjuvant whole cell tumor vaccine for cancer immunotherapy. Biomaterials. 2013;34(33):8291-8300.
7. Fang RH, Hu CJ, Luk BT, et al. Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery. Nano letters. 2014;14(4):2181-2188.
8. Sehgal K, Ragheb R, Fahmy TM, Dhodapkar MV, Dhodapkar KM. Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk. J Immunol. 2014;193(5):2297-2305.
9. Jeanbart L, Ballester M, de Titta A, et al. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. Cancer Immunol Res. 2014;2(5):436-447.
10. Ahn S, Lee I, Kang S, et al. Gold Nanoparticles Displaying Tumor-Associated Self-Antigens as a Potential Vaccine for Cancer Immunotherapy. Advanced healthcare materials. 2014.
11. Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nature Reviews Clinical Oncology. 2013.
12. Ray A, Dittel BN. Isolation of mouse peritoneal cavity cells. J Vis Exp. 2010;(35): pii1488.
13. Zhang X, Goncalves R, Mosser DM. The isolation and characterization of murine macrophages. Current protocols in immunology. 2008;:14.1.1-14.1.14.
14. Koido S, Enomoto Y, Apostolopoulos V, Gong J. Tumor regression by CD4 T-cells primed with dendritic/tumor fusion cell vaccines. Anticancer Res. 2014;34(8):3917-3924.
15. Martinez-Pomares L, Gordon S. CD169 macrophages at the crossroads of antigen presentation. Trends Immunol. 2012;33(2):66-70.
16. Asano K, Nabeyama A, Miyake Y, et al. CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity. 2011;34(1):85-95.
17. Ireland JM, Unanue ER. Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells. J Exp Med. 2011;208(13):2625-2632.
18. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol. 1999;1(6):362-368.
19. Garin J, Diez R, Kieffer S, et al. The phagosome proteome: insight into phagosome functions. J Cell Biol. 2001;152(1):165-180.
20. Houde M, Bertholet S, Gagnon E, et al. Phagosomes are competent organelles for antigen cross-presentation. Nature. 2003;425(6956):402-406.
21. Brode S, Macary PA. Cross-presentation: dendritic cells and macrophages bite off more than they can chew! Immunology. 2004;112(3):345-351.
22. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol. 2005;174(2):636-645.
23. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. The Lancet. 2008;371(9614):771-783.
24. Lyamina S, Kruglov S, Vedenikin TY, et al. Alternative Reprogramming of M1/M2 Phenotype of Mouse Peritoneal Macrophages In Vitro with Interferon-γ and Interleukin-4. Bull Exp Biol Med. 2012;152(4):548-551.